Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
Not Confirmed
Not Confirmed
07-09 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Industry Trade Show
Not Confirmed
07-09 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-s-landmark-approvals-of-bms-schizo-med-madrigal-s-mash-drug-us-16-5-bn-catalent-buyout-make-it-to-top-10-news-of-2024
30 Sep 2024
// BUSINESSWIRE
13 Jun 2023
// Kyle LaHucik ENDPTS
https://endpts.com/incarda-terminates-phiii-trial-of-its-inhaled-atrial-fibrillation-drug/
31 Aug 2022
// Joseph Keenan FIERCEBIOTECH
https://www.fiercebiotech.com/cro/incarda-physiq-and-syneos-team-phase-3-flecainide-study
24 Aug 2022
// BUSINESSWIRE
10 Jun 2021
// BIOSPACE
https://www.biospace.com/article/-incarda-therapeutics-provides-corporate-update-highlighting-new-phase-2-data-for-inrhythm-program-plans-for-pivotal-phase-3-study-and-expansion-of-senior-management-team/
09 Jun 2021
// Max Gelman ENDPTS
https://endpts.com/with-its-eyes-set-on-an-ipo-raise-incarda-preps-to-unroll-mid-stage-data-backing-inhaled-arrhythmia-drug/
Details:
FlecIH-103 is a novel inhaled drug designed to rapidly deliver flecainide acetate, to the heart via the lungs to restore normal sinus rhythm in patient’s symptoms recurrent PAF.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: FlecIH-103
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2024
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
InCarda Announces RESTORE-1 Phase 3 Trial Results and Continued Development Plans
Details : FlecIH-103 is a novel inhaled drug designed to rapidly deliver flecainide acetate, to the heart via the lungs to restore normal sinus rhythm in patient’s symptoms recurrent PAF.
Brand Name : FlecIH-103
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 30, 2024
Details:
Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Inrhythm
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: PhysIQ
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2022
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : PhysIQ
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.
Brand Name : Inrhythm
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 24, 2022
Details:
Based on these positive Phase 2 study results, along with recent interactions with the U.S. Food and Drug Administration (FDA), InCarda plans to conduct a single pivotal Phase 3 trial of InRhythm in patients with recent-onset PAF.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: InRhythm
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2021
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm Program
Details : Based on these positive Phase 2 study results, along with recent interactions with the U.S. Food and Drug Administration (FDA), InCarda plans to conduct a single pivotal Phase 3 trial of InRhythm in patients with recent-onset PAF.
Brand Name : InRhythm
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 09, 2021
Details:
The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: FlecIH
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series C Financing October 21, 2020
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Innoviva
Deal Size : Undisclosed
Deal Type : Series C Financing
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
Details : The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.
Brand Name : FlecIH
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 21, 2020
Details:
Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: InRhythm
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Deerfield Management
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 21, 2020
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Deerfield Management
Deal Size : $30.0 million
Deal Type : Series C Financing
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
Details : Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).
Brand Name : InRhythm
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 21, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?